Best Biotech & Longevity Companies & Apps (2026)

Biotech is being reinvented by software. AI-first drug discovery companies (Recursion, Insitro, Insilico Medicine) have raised $10B+ combined, and the first AI-discovered drugs are entering Phase II clinical trials. The promise: reducing the average $2.6B cost and 10-year timeline of bringing a drug to market by 50-70%. The longevity sector has gone from fringe to mainstream. Altos Labs ($3B from Jeff Bezos), Calico (Google), and Unity Biotechnology are pursuing cellular reprogramming, senolytic therapies, and epigenetic clocks. Bryan Johnson's Blueprint protocol has turned anti-aging into a consumer movement. The science is real: rapamycin, metformin, and NAD+ precursors show genuine promise in clinical settings. What makes modern biotech different from the last generation is the convergence of AI, CRISPR, and cloud biology. Startups can now screen millions of compounds computationally, edit genes with precision, and run experiments on robotic lab platforms (Strateos, Emerald Cloud Lab). This dramatically reduces the capital required to reach clinical-stage data, making biotech fundable for VCs who previously avoided the space. The TAM is healthcare itself, a $12T global market.